menu
    • menu
    [{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"HCW9218","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Not Applicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Not Applicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ University of Minnesota","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ University of Minnesota"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Not Applicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ Not Applicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"HCW9302","moa":"Tregs","graph1":"Immunology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Not Applicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Prime Capital Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"HCW9218","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HCW Biologics \/ Prime Capital Ventures","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Prime Capital Ventures"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"WY Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HCW Biologics \/ WY Biotech","highestDevelopmentStatusID":"4","companyTruncated":"HCW Biologics \/ WY Biotech"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"HCW9302","moa":"IL-2R","graph1":"Dermatology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by HCW Biologics

    Menu

    HCW Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9302

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HCW Biologics Gets FDA Nod for First-In-Human Phase 1 Trial

                            Details : HCW9302 is an injectable, first-in-kind interleukin 2 fusion protein complex, which is being evaluated in patients with moderate-to-severe alopecia areata.

                            Product Name : HCW9302

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 03, 2025

                            Lead Product(s) : HCW9302

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : WY Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            HCW Biologics, WY Biotech Announce License Agreement for Immunotherapeutic Product

                            Details : Under the agreement, WY Biotech will develop and commercialize one of HCWB’s product candidates generated with its new drug discovery platform for therapeutic use.

                            Product Name : 7

                            Product Type : Large molecule

                            Upfront Cash : $7.0 million

                            November 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : WY Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Prime Capital Ventures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

                            Details : The net proceeds will fund multiple Phase 2 trials in cancer, to evaluate HCW9218, the Company’s injectable, bifunctional fusion protein for reduction of senescence; and a Phase 1b study in an autoimmune disease to evaluate HCW9302, an injectable, IL-2...

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 27, 2023

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Prime Capital Ventures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9302

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

                            Details : Preclinical studies in mouse models have demonstrated the ability of HCW9302 to activate Treg cells and reduce inflammation-related disease pathologies, supporting the potential of HCW9302 to treat a wide variety of autoimmune and proinflammatory disease...

                            Product Name : HCW9302

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 02, 2022

                            Lead Product(s) : HCW9302

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference, May 23-25, 2022

                            Details : HCW9218 is novel bi-functional fusion protein complex administered by injection. It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and human IL-15, and second soluble fusion of two human TGFβRII domains and a sushi ...

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 23, 2022

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HCW Biologics CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on ...

                            Details : Preclinical data from in vivo animal studies demonstrated ability of HCW9218, to both enhance anti-tumor efficacy of chemotherapy drugs and diminish their harmful side effects by reducing therapy-induced senescence and eliminating TGF-β and its immunosu...

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : University of Minnesota

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical T...

                            Details : UM cleared to proceed with clinical trial to evaluate HCW9218, activates IL-15R signaling in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers.

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 24, 2022

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : University of Minnesota

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for...

                            Details : HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2021

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218

                            Details : HCW9218 is a heterodimeric, bifunctional fusion protein complex comprising extracellular domains of the human TGF-β receptor II, as TGF-β trap for TGF-β neutralization, and a human interleukin (IL)-15/IL-15 receptor α complex for immune-cell stimulat...

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 24, 2021

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            HCW Biologics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            HCW Files for $50M IPO to Trial Fusion Protein in Solid Tumors

                            Details : HCW9218, a bifunctional fusion protein, displayed strong anti-tumor activity mediated by NK cells and CD8+ T cells, and increased infiltration of NK cells and CD8+ T cells into tumors.

                            Product Name : HCW9218

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 28, 2021

                            Lead Product(s) : HCW9218

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth